Citigroup Has Lowered Expectations for Apellis Pharmaceuticals (NASDAQ:APLS) Stock Price
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective reduced by Citigroup from $49.00 to $41.00 in a report issued on Thursday morning,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other brokerages have also recently commented on APLS. Robert W. Baird dropped their target price on Apellis Pharmaceuticals from $55.00 […]
Apellis Pharmaceuticals (NASDAQ:APLS – Free Report) had its price objective reduced by Citigroup from $49.00 to $41.00 in a report issued on Thursday morning,Benzinga reports. Citigroup currently has a buy rating on the stock. Several other brokerages have also recently commented on APLS. Robert W. Baird dropped their target price on Apellis Pharmaceuticals from $55.00 […]
